61/100BGenmab A executives and insider trading
Jan van de Winkel reported no open-market purchases or sales over the last twelve months.
Over the last twelve months Genmab A/S ADS's insiders sold 0 shares for 0 USD in 0 sales on the open market, and bought 0 shares in 0 purchases.
Insiders over the last twelve months
- Insider sales
- 0
- Shares sold
- —
- Value sold
- —
- Insider purchasesWhat is insider trading? Insider trading here means the legal trades that a company's executives, directors and large owners make in its shares, reported to the SEC on Form 4.
- 0
Insiders buying against sellingWhat is a Rule 10b5-1 trading plan? A Rule 10b5-1 plan lets an insider fix future trades in advance, while holding no inside information, so later trades follow the plan, not a new decision.
Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).
Executives and directors
The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.
| Name | Position | Age | Shares sold (12 months) | Value sold (12 months) | Shares bought (12 months) | Last sale | Shares held after |
|---|---|---|---|---|---|---|---|
| Jan van de Winkel CEO | Co-Founder, President & Chief Executive Officer | 65 | — | — | — | — | — |
| Judith V. Klimovsky | Executive Vice President & Chief Development Officer | 68 | — | — | — | — | — |
| Martine J. van Vugt | Executive Vice President & Chief Strategy Officer | 55 | — | — | — | — | — |
| Christopher Cozic | Executive Vice President & Chief People Officer | 48 | — | — | — | — | — |
| Gregory David Emil Mueller | Executive VP, General Counsel & Chief Legal Officer | 55 | — | — | — | — | — |
| Rayne Waller | Executive Vice President & Chief Technical Operations Officer | 58 | — | — | — | — | — |
| Anthony Pagano | Executive Vice President & Chief Financial Officer | 48 | — | — | — | — | — |
| Martin Schultz | Senior Director, Head of Development Business Partnership & Strategy and Director | 51 | — | — | — | — | — |
| Tahamtan Ahmadi | Executive Vice President, Chief Medical Officer & Head of Experimental Medicines | 53 | — | — | — | — | — |
| Mijke Zachariasse | Vice President, Head of Antibody Research Materials & Director | 53 | — | — | — | — | — |
Every insider transactionWhat is insider trading? Insider trading here means the legal trades that a company's executives, directors and large owners make in its shares, reported to the SEC on Form 4.
Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.
| Date | Name | Transaction | Shares | Price | Value | Shares held after | Filing |
|---|
Common questions about Genmab A's executives and insiders
Source: Financial Modeling Prep